Advances in androgen receptor targeted therapy for prostate cancer

Journal of Cellular Physiology

Volumn 229, Issue 3, 2014, Pages 271-276

  Ahmed, Alia ^a   Ali, Shadan ^a   Sarkar, Fazlul H ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE ACETATE; ANDROGEN; ANDROGEN RECEPTOR; ANTIANDROGEN; ANTINEOPLASTIC AGENT; ARN 509; BICALUTAMIDE; CORTICOSTEROID; CURCUMIN; DIHYDROXYTESTOSTERONE; ENZALUTAMIDE; FOLLITROPIN; GREEN TEA EXTRACT; HEAT SHOCK PROTEIN 90 INHIBITOR; HYDROCORTISONE; INDOLE DERIVATIVE; ISOFLAVONE DERIVATIVE; KETOCONAZOLE; LEUPRORELIN; LUTEINIZING HORMONE; ORTERONEL; PLACEBO; PROSTATE SPECIFIC ANTIGEN; SELENIUM; TESTOSTERONE; UNCLASSIFIED DRUG;

ANDROGEN BLOOD LEVEL; ANDROGEN DEPRIVATION THERAPY; ANDROGEN SYNTHESIS; ANTIANDROGEN THERAPY; APOPTOSIS; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CELL PROLIFERATION; CLINICAL EFFECTIVENESS; CORTICOSTEROID BLOOD LEVEL; DRUG BINDING SITE; DRUG DNA BINDING; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; FATIGUE; HORMONE RELEASE; HORMONE SYNTHESIS; HOT FLUSH; HUMAN; HYDROCORTISONE BLOOD LEVEL; NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POINT MUTATION; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROTEIN FUNCTION; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; UPREGULATION;

ANDROGEN ANTAGONISTS; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; DRUG DESIGN; HUMANS; LIGANDS; MALE; MOLECULAR TARGETED THERAPY; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84888053623     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24456     Document Type: Review

References (65)

1. Ahmad A, Kong D, Sarkar SH, Wang Z, Banerjee S, Sarkar FH. 2009. Inactivation of uPA and its receptor uPAR by 3, 3′-diindolylmethane (DIM) leads to the inhibition of prostate cancer cell growth and migration. J Cell Biochem 107:516-527.
2. Attard G, Richards J, de Bono JS. 2011. New strategies in metastatic prostate cancer: Targeting the androgen receptor signaling pathway. Clin Cancer Res 17:1649-1657.
3. Bao B, Ali S, Kong D, Sarkar SH, Wang Z, Banerjee S, Aboukameel A, Padhye S, Philip PA, Sarkar FH. 2011. Anti-tumor activity of a novel compound-CDF is mediated by regulating miR-21, miR-200, and PTEN in pancreatic cancer. PLoS ONE 6:e17850.
4. Bhuiyan MM, Li Y, Banerjee S, Ahmed F, Wang Z, Ali S, Sarkar FH. 2006. Down-regulation of androgen receptor by 3, 3′-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in both hormone-sensitive LNCaP and insensitive C4-2B prostate cancer cells. Cancer Res 66:10064-10072.
5. Burki TK. 2013. Abiraterone and castration-resistant prostate cancer. Lancet Oncol 14:e48.
6. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL. 2004. Molecular determinants of resistance to antiandrogen therapy. Nat Med 10:33-39.
7. Chen Y, Clegg NJ, Scher HI. 2009. Anti-androgens and androgen-depleting therapies in prostate cancer: New agents for an established target. Lancet Oncol 10:981-991.
8. Choi S, Lee AK. 2011. Efficacy and safety of gonadotropin-releasing hormone agonists used in the treatment of prostate cancer. Drug Healthc Patient Saf 3:107-119.
9. Clegg NJ, Wongvipat J, Joseph JD, Tran C, Ouk S, Dilhas A, Chen Y, Grillot K, Bischoff ED, Cai L, Aparicio A, Dorow S, Arora V, Shao G, Qian J, Zhao H, Yang G, Cao C, Sensintaffar J, Wasielewska T, Herbert MR, Bonnefous C, Darimont B, Scher HI, Smith-Jones P, Klang M, Smith ND, De SE, Wu N, Ouerfelli O, Rix PJ, Heyman RA, Jung ME, Sawyers CL, Hager JH. 2012. ARN-509: A novel antiandrogen for prostate cancer treatment. Cancer Res 72:1494-1503.
10. Dayyani F, Gallick GE, Logothetis CJ, Corn PG. 2011. Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst 103:1665-1675.
11. De Leon JT, Iwai A, Feau C, Garcia Y, Balsiger HA, Storer CL, Suro RM, Garza KM, Lee S, Kim YS, Chen Y, Ning YM, Riggs DL, Fletterick RJ, Guy RK, Trepel JB, Neckers LM, Cox MB. 2011. Targeting the regulation of androgen receptor signaling by the heat shock protein 90 cochaperone FKBP52 in prostate cancer cells. Proc Natl Acad Sci USA 108:11878-11883.
12. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ. 2008. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 68:5469-5477.
13. Desiniotis A, Schafer G, Klocker H, Eder IE. 2010. Enhanced antiproliferative and proapoptotic effects on prostate cancer cells by simultaneously inhibiting androgen receptor and cAMP-dependent protein kinase A. Int J Cancer 126:775-789.
14. Dumas L, Payne H, Chowdhury S. 2012. The evolution of antiandrogens: MDV3100 comes of age. Expert Rev Anticancer Ther 12:131-133.
15. Edwards J, Krishna NS, Grigor KM, Bartlett JM. 2003. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer 89:552-556.
16. Ferraldeschi R, Pezaro C, Karavasilis V, de BJ. 2013. Abiraterone and novel antiandrogens: Overcoming castration resistance in prostate cancer. Annu Rev Med 64:1-13.
17. Golshayan AR, Antonarakis ES. 2013. Enzalutamide: An evidence-based review of its use in the treatment of prostate cancer. Core Evid 8:27-35.
18. Grimm P, Billiet I, Bostwick D, Dicker AP, Frank S, Immerzeel J, Keyes M, Kupelian P, Lee WR, Machtens S, Mayadev J, Moran BJ, Merrick G, Millar J, Roach M, Stock R, Shinohara K, Scholz M, Weber E, Zietman A, Zelefsky M, Wong J, Wentworth S, Vera R, Langley S. 2012. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int 109:22-29.
19. Guerrero J, Alfaro IE, Gomez F, Protter AA, Bernales S. 2013. Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer. Prostate 73:1291-1305.
20. Hara T, Kouno J, Kaku T, Takeuchi T, Kusaka M, Tasaka A, Yamaoka M. 2013. Effect of a novel 17, 20-lyase inhibitor, orteronel (TAK-700), on androgen synthesis in male rats. J Steroid Biochem Mol Biol 134:80-91.
21. Hay CW, McEwan IJ. 2012. The impact of point mutations in the human androgen receptor: Classification of mutations on the basis of transcriptional activity. PLoS ONE 7:e32514.
22. He S, Zhang C, Shafi AA, Sequeira M, Acquaviva J, Friedland JC, Sang J, Smith DL, Weigel NL, Wada Y, Proia DA. 2013. Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression. Int J Oncol 42:35-43.
23. Heidegger I, Massoner P, Eder IE, Pircher A, Pichler R, Aigner F, Bektic J, Horninger W, Klocker H. 2013. Novel therapeutic approaches for the treatment of castration-resistant prostate cancer. J Steroid Biochem Mol Biol 138:248-256.
24. Hu R, Lu C, Mostaghel EA, Yegnasubramanian S, Gurel M, Tannahill C, Edwards J, Isaacs WB, Nelson PS, Bluemn E, Plymate SR, Luo J. 2012. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res 72:3457-3462.
25. Kim W, Ryan CJ. 2012. Androgen receptor directed therapies in castration-resistant metastatic prostate cancer. Curr Treat Options Oncol 13:189-200.
26. Kim YS, Kumar V, Lee S, Iwai A, Neckers L, Malhotra SV, Trepel JB. 2012. Methoxychalcone inhibitors of androgen receptor translocation and function. Bioorg Med Chem Lett 22:2105-2109.
27. Leibowitz-Amit R, Joshua AM. 2012. Targeting the androgen receptor in the management of castration-resistant prostate cancer: Rationale, progress, and future directions. Curr Oncol 19:S22-S31.
28. Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA, Dehm SM. 2013. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res 73:483-489.
29. Li Y, Kong D, Ahmad A, Bao B, Sarkar FH. 2012. Targeting bone remodeling by isoflavone and 3, 3′-diindolylmethane in the context of prostate cancer bone metastasis. PLoS ONE 7:e33011.
30. Li Y, Kong D, Wang Z, Ahmad A, Bao B, Padhye S, Sarkar FH. 2011. Inactivation of AR/TMPRSS2-ERG/Wnt signaling networks attenuates the aggressive behavior of prostate cancer cells. Cancer Prev Res (Phila) 4:1495-1506.
31. Massard C, Fizazi K. 2011. Targeting continued androgen receptor signaling in prostate cancer. Clin Cancer Res 17:3876-3883.
32. Menon MP, Higano CS. 2013. Enzalutamide, a second generation androgen receptor antagonist: Development and clinical applications in prostate cancer. Curr Oncol Rep 15:69-75.
33. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, True LD, Nelson PS. 2008. Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth. Cancer Res 68:4447-4454.
34. Mostaghel EA, Montgomery B, Nelson PS. 2009. Castration-resistant prostate cancer: Targeting androgen metabolic pathways in recurrent disease. Urol Oncol 27:251-257.
35. Osguthorpe DJ, Hagler AT. 2011. Mechanism of androgen receptor antagonism by bicalutamide in the treatment of prostate cancer. Biochemistry 50:4105-4113.
36. Padhye S, Yang H, Jamadar A, Cui QC, Chavan D, Dominiak K, McKinney J, Banerjee S, Dou QP, Sarkar FH. 2009. New difluoro Knoevenagel condensates of curcumin, their Schiff bases and copper complexes as proteasome inhibitors and apoptosis inducers in cancer cells. Pharm Res 26:1874-1880.
37. Peacock SO, Fahrenholtz CD, Burnstein KL. 2012. Vav3 enhances androgen receptor splice variant activity and is critical for castration-resistant prostate cancer growth and survival. Mol Endocrinol 26:1967-1979.
38. Prins GS, Putz O. 2008. Molecular signaling pathways that regulate prostate gland development. Differentiation 76:641-659.
39. Richards J, Lim AC, Hay CW, Taylor AE, Wingate A, Nowakowska K, Pezaro C, Carreira S, Goodall J, Arlt W, McEwan IJ, de Bono JS, Attard G. 2012. Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: A rationale for increasing abiraterone exposure or combining with MDV3100. Cancer Res 72:2176-2182.
40. Roychowdhury S, Chinnaiyan AM. 2013. Advancing precision medicine for prostate cancer through genomics. J Clin Oncol 31:1866-1873.
41. Sahu B, Laakso M, Ovaska K, Mirtti T, Lundin J, Rannikko A, Sankila A, Turunen JP, Lundin M, Konsti J, Vesterinen T, Nordling S, Kallioniemi O, Hautaniemi S, Janne OA. 2011. Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer. EMBO J 30:3962-3976.
42. Sampson N, Neuwirt H, Puhr M, Klocker H, Eder IE. 2013. In vitro model systems to study androgen receptor signaling in prostate cancer. Endocr Relat Cancer 20:R49-R64.
43. Saporita AJ, Ai J, Wang Z. 2007. The Hsp90 inhibitor, 17-AAG, prevents the ligand-independent nuclear localization of androgen receptor in refractory prostate cancer cells. Prostate 67:509-520.
44. Sarkar FH, Li Y, Wang Z, Kong D. 2010. Novel targets for prostate cancer chemoprevention. Endocr Relat Cancer 17:R195-R212.
45. Sartor O, Michels RM, Massard C, de Bono JS. 2011. Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting. Oncologist 16:1487-1497.
46. Sasse AD, Sasse E, Carvalho AM, Macedo LT. 2012. Androgenic suppression combined with radiotherapy for the treatment of prostate adenocarcinoma: A systematic review. BMC Cancer 12:54.
47. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J, Hung D, Hirmand M, Seely L, Morris MJ, Danila DC, Humm J, Larson S, Fleisher M, Sawyers CL. 2010. Antitumour activity of MDV3100 in castration-resistant prostate cancer: A phase1-2 study. Lancet 375:1437-1446.
48. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de WR, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Flechon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS. 2012. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367:1187-1197.
49. Schweizer MT, Antonarakis ES. 2012. Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: A new era of hormonal therapies is born. Ther Adv Urol 4:167-178.
50. Shafi AA, Cox MB, Weigel NL. 2013. Androgen receptor splice variants are resistant to inhibitors of Hsp90 and FKBP52, which alter androgen receptor activity and expression. Steroids 78:548-554.
51. Sharma NL, Massie CE, Ramos-Montoya A, Zecchini V, Scott HE, Lamb AD, MacArthur S, Stark R, Warren AY, Mills IG, Neal DE. 2013. The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man. Cancer Cell 23:35-47.
52. Siegel R, Naishadham D, Jemal A. 2013. Cancer statistics, 2013. CA Cancer J Clin 63:11-30.
53. Small EJ, Baron A, Bok R. 1997. Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma. Cancer 80:1755-1759.
54. Snoek R, Cheng H, Margiotti K, Wafa LA, Wong CA, Wong EC, Fazli L, Nelson CC, Gleave ME, Rennie PS. 2009. In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors. Clin Cancer Res 15:39-47.
55. Stein MN, Goodin S, Dipaola RS. 2012. Abiraterone in prostate cancer: A new angle to an old problem. Clin Cancer Res 18:1848-1854.
56. Taneja SS. 2013. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: Exploratory analysis of data from the COU-AA-301 randomised trial. J Urol 189:1715.
57. Taplin ME, Rajeshkumar B, Halabi S, Werner CP, Woda BA, Picus J, Stadler W, Hayes DF, Kantoff PW, Vogelzang NJ, Small EJ. 2003. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol 21:2673-2678.
58. Thompson VC, Day TK, Bianco-Miotto T, Selth LA, Han G, Thomas M, Buchanan G, Scher HI, Nelson CC, Greenberg NM, Butler LM, Tilley WD. 2012. A gene signature identified using a mouse model of androgen receptor-dependent prostate cancer predicts biochemical relapse in human disease. Int J Cancer 131:662-672.
59. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, Hung DT, Scher HI, Jung ME, Sawyers CL. 2009. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324:787-790.
60. Turitto G, Di BM, Moraca L, Sasso N, Sepede C, Suriano A, Romito S. 2012. Abiraterone acetate: A novel therapeutic option in hormone-refractory prostate cancer. Recenti Prog Med 103:74-78.
61. Wang Z, Gao D, Fukushima H, Inuzuka H, Liu P, Wan L, Sarkar FH, Wei W. 2012. Skp2: A novel potential therapeutic target for prostate cancer. Biochim Biophys Acta 1825:11-17.
62. Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, Viale A, Kim K, Sawyers CL. 2010. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci USA 107:16759-16765.
63. Xu Y, Jiang YF, Wu B. 2012. New agonist- and antagonist-based treatment approaches for advanced prostate cancer. J Int Med Res 40:1217-1226.
64. Yamaoka M, Hara T, Hitaka T, Kaku T, Takeuchi T, Takahashi J, Asahi S, Miki H, Tasaka A, Kusaka M. 2012. Orteronel (TAK-700), a novel non-steroidal 17, 20-lyase inhibitor: Effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys. J Steroid Biochem Mol Biol 129:115-128.
65. Zhu H, Garcia JA. 2013. Targeting the adrenal gland in castration-resistant prostate cancer: A case for orteronel, a selective CYP-17 17, 20-lyase inhibitor. Curr Oncol Rep 15:105-112.